Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

NASDAQ:IONS

Ionis Pharmaceuticals, Inc.

Last Close

41.59

29/04 14:58

Market Cap

6.06B

Beta: 0.54

Volume Today

99.73K

Avg: 904.55K

PE Ratio

−17.34

PFCF: −15.39

Please Sign In To Use The Chat